- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06167629
Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer
Study Overview
Detailed Description
In this study, all PET images with 18F-PSMA will be considered, but also the CT or MR images associated with them to allow better anatomical localization.
This study will allow us to investigate the diagnostic and prognostic role of l8F-PSMA PET, also evaluating its predictive value in terms of disease course, development of metastases and mortality. The retrospective part of this protocol is necessary for the acquisition of a sufficiently large amount of data to guarantee adequate statistical power for the study.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Arturo Chiti
- Phone Number: 0226432716
- Email: chiti.arturo@hsr.it
Study Contact Backup
- Name: Alessandra Maielli
- Phone Number: 0226432716
- Email: maielli.alessandra@hsr.it
Study Locations
-
-
-
Milano, Italy
- Recruiting
- IRC
-
Contact:
- Arturo Chiti
- Email: chiti.arturo@hsr.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- adult male patients;
- patients with histopathological diagnosis of prostate cancer undergoing staging or restaging;
- patients with clinical indication for PET examination with 18 F-PSMA;
Exclusion Criteria:
- medical conditions that do not allow the acquisition of PET images;
- allergic reactions to iodinated contrast medium or creatinine levels >2mg/dL.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PET with 18F-PSMA for diagnostic accuracy for staging of prostate cancer.
Time Frame: 5 years
|
the role of a quantitative-semi-quantitative analysis for the characterization of prostatic pathology in different phases of the disease.
|
5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OMNIA_PSMA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.